Former U.S. Surgeon General Jerome Adams published an opinion piece calling on the FDA to adopt a structured, clinician-guided framework for regulating peptides. The commentary, which appeared in STAT News, argues against both a blanket ban and unchecked availability.
Adams positions his proposal as a middle-ground approach that would allow access while ensuring medical oversight. The peptide market has expanded rapidly in recent years, driven by interest in areas such as anti-aging and metabolic health. This growth has prompted regulatory debates amid concerns over safety and efficacy claims.
The former surgeon general did not specify which peptides require the most urgent regulation or offer a timeline for the framework. His op-ed serves more as a policy direction than a detailed regulatory blueprint. No specific data on market size or adverse events was cited in the piece.
If the FDA follows this guidance, it could reshape how peptides reach consumers, potentially limiting direct-to-patient sales while expanding clinician involvement. Manufacturers and telehealth companies that currently operate with minimal oversight may face new compliance requirements.
Adams did not address potential industry pushback or how enforcement would work in practice. The piece reflects one expert viewpoint rather than official FDA policy.